Kanaph Therapeutics Company Profile
Kanaph Therapeutics Inc, founded in 2019 and headquartered in Seoul, South Korea, is a public biotech company specializing in human genome-based drug development for anticancer and ophthalmic treatments, with a pipeline including bispecific antibodies and ADCs, a market cap of $168M as of mid-2026, trailing 12-month revenue of $3.95M, significant net losses, and a robust patent portfolio comprising 87 documents across 20 families.
Overview
Kanaph Therapeutics Inc is a biotech company focused on developing anticancer drugs and treatments for ophthalmic diseases using human genome-based drug development technology. The company identifies novel targets with high unmet medical needs through analysis of human genome data and disease-specific biological signatures. It develops drugs of various modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and synthetic drugs. The pipeline products include KNP-101, KNP-301, KNP-502, KNP-503, KNP-504, and KNP-701.
- Year Founded: 2019
- Status: Public
- Employees: 30
- Stock Symbol: 0082N0
- Share Price: $12.81 (as of Monday closing)
- Headquarters: 5th Floor, 3 Itaewon-ro 55ga-gil, Seoul, Yongsan 04348, South Korea
- Website: www.kanaphtx.com
- Primary Industry: Drug Discovery
- Other Industries: Biotechnology
- Stock Exchange: KRX
- Verticals: HealthTech, Life Sciences, Oncology
Stock Performance (as of 15-Jun-2026)
- Stock Price: $12.81
- Previous Close: $12.85
- 52 Week Range: $11.28 - $37.75
- Market Cap: $168M
- Shares Outstanding: 13.1M
- Average Volume: 436K
- EPS: -$3.67
Financials Summary (as of 31-Mar-2026)
- Trailing 12-Month Revenue: $3.95M
| Metric | TTM 31-Mar-2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| EV | 287,909 | |||
| Revenue | 3,954 | 3,907 | 3,116 | 267 |
| EBITDA | (24,191) | (21,910) | (16,790) | (6,557) |
| Net Income | (26,262) | (24,987) | (20,720) | (9,626) |
| Total Assets | 34,043 | 10,737 | 13,594 | 15,689 |
| Total Debt | 150 | 212 | 332 | 195 |
Patents
- Total Documents (Applications and Grants): 87
- Total Patent Families: 20
- Granted: 20
- Pending: 50
- Expiring in next 12 months: Not specified
Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026038916-A1 | Novel compound having sos1 inhibitory activity | Pending | 14-Aug-2024 | ||
| AU-2024220775-A1 | Azolylpyridine pyridazinone amide as sos1 inhibitor | Pending | 16-Feb-2023 | ||
| EP-4667464-A1 | Azolylpyridine pyridazinone amide as sos1 inhibitor | Pending | 16-Feb-2023 | ||
| WO-2024172632-A1 | Azolylpyridine pyridazinone amide as sos1 inhibitor | Inactive | 16-Feb-2023 | ||
| JP-2026507483-A | Azolylpyridine pyridazinone amides as sos1 inhibitors | Pending | 16-Feb-2023 | C07D401/14 |
FAQs
When was Kanaph Therapeutics founded?
Kanaph Therapeutics was founded in 2019.
Where is Kanaph Therapeutics headquartered?
Kanaph Therapeutics is headquartered in Seoul, South Korea.
What is the size of Kanaph Therapeutics?
Kanaph Therapeutics has 30 total employees.
What industry is Kanaph Therapeutics in?
Kanaph Therapeutics’s primary industry is Drug Discovery.
Is Kanaph Therapeutics a private or public company?
Kanaph Therapeutics is a Public company.
What is Kanaph Therapeutics’s stock symbol?
The ticker symbol for Kanaph Therapeutics is 0082N0.
What is the current stock price of Kanaph Therapeutics?
As of 15-Jun-2026 the stock price of Kanaph Therapeutics is $12.81.
What is the current market cap of Kanaph Therapeutics?
The current market capitalization of Kanaph Therapeutics is $168M.
What is Kanaph Therapeutics’s current revenue?
The trailing twelve month revenue for Kanaph Therapeutics is $3.95M.
What is Kanaph Therapeutics’s annual earnings per share (EPS)?
Kanaph Therapeutics’s EPS for 12 months was -$3.67.